uniQure N.V.

NASDAQ (USD): uniQure N.V. (QURE)

Last Price

14.35

Today's Change

-0.95 (6.20%)

Day's Change

14.21 - 15.20

Trading Volume

576,164

Profile
QURE

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Matthew Craig Kapusta CPA Mr. Matthew Craig Kapusta CPA

Full Time Employees:  480 480

IPO Date:  2014-02-05 2014-02-05

CIK:  0001590560 0001590560

ISIN:  NL0010696654 NL0010696654

CUSIP:  N90064101 N90064101

Beta:  0.90 0.90

Last Dividend:  0.00 0.00

Dcf Diff:  20.41 20.41

Dcf:  -2.75 -2.75

Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Address

Paasheuvelweg 25a,
Amsterdam, 1105 BP, NL

31 20 240 6000

http://www.uniqure.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment